De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
ADMA Biologics Beheer
Beheer criteriumcontroles 3/4
De CEO ADMA Biologics' is Adam Grossman, benoemd in Jan2007, heeft een ambtstermijn van 17.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.04M, bestaande uit 12.4% salaris en 87.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.07% van de aandelen van het bedrijf, ter waarde $ 49.71M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.8 jaar en 12.3 jaar.
Belangrijke informatie
Adam Grossman
Algemeen directeur
US$6.0m
Totale compensatie
| Percentage CEO-salaris | 12.4% |
| Dienstverband CEO | 17.8yrs |
| Eigendom CEO | 1.1% |
| Management gemiddelde ambtstermijn | less than a year |
| Gemiddelde ambtstermijn bestuur | 12.3yrs |
Recente managementupdates
Recent updates
ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues
Oct 09
ADMA Biologics: Riding High On ASCENIV's Success
Oct 02ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price
Sep 06ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality
Aug 16ADMA Biologics: A Compelling GARP Stock For Biotech Investors
Jul 27ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 24Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?
May 30ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
May 13Giving ADMA Biologics A Well-Deserved 'Booyah'
May 12ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
May 08Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Apr 03ADMA Biologics: On A Roll Entering 2024
Jan 19Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Jan 09ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Jan 09We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet
May 12ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
Aug 21ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M
Aug 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics: A Path To Profits Looks Clear
May 12ADMA: Pertinent Updates
Apr 18ADMA Biologics' 2021 Numbers Showed Continued Strong Execution
Mar 29ADMA Biologics: 2021 Was Tough
Jan 18ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Dec 02Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$35m |
| Mar 31 2024 | n/a | n/a | -US$4m |
| Dec 31 2023 | US$6m | US$750k | -US$28m |
| Sep 30 2023 | n/a | n/a | -US$23m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$48m |
| Dec 31 2022 | US$3m | US$637k | -US$66m |
| Sep 30 2022 | n/a | n/a | -US$70m |
| Jun 30 2022 | n/a | n/a | -US$73m |
| Mar 31 2022 | n/a | n/a | -US$78m |
| Dec 31 2021 | US$4m | US$618k | -US$72m |
| Sep 30 2021 | n/a | n/a | -US$74m |
| Jun 30 2021 | n/a | n/a | -US$74m |
| Mar 31 2021 | n/a | n/a | -US$75m |
| Dec 31 2020 | US$2m | US$600k | -US$76m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Jun 30 2020 | n/a | n/a | -US$61m |
| Mar 31 2020 | n/a | n/a | -US$54m |
| Dec 31 2019 | US$2m | US$536k | -US$48m |
| Sep 30 2019 | n/a | n/a | -US$56m |
| Jun 30 2019 | n/a | n/a | -US$59m |
| Mar 31 2019 | n/a | n/a | -US$61m |
| Dec 31 2018 | US$2m | US$536k | -US$66m |
| Sep 30 2018 | n/a | n/a | -US$61m |
| Jun 30 2018 | n/a | n/a | -US$61m |
| Mar 31 2018 | n/a | n/a | -US$55m |
| Dec 31 2017 | US$3m | US$494k | -US$44m |
Compensatie versus markt: De totale vergoeding ($USD 6.04M ) Adam } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.75M ).
Compensatie versus inkomsten: De vergoeding van Adam is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Adam Grossman (47 yo)
17.8yrs
Tenure
US$6,039,649
Compensatie
Mr. Adam S. Grossman serves as Director at BioFlorida Inc since August 2021. He is the Co-Founder of ADMA Biologics, Inc. and has been its Chief Executive Officer and President since October 2011 and 2007...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 17.8yrs | US$6.04m | 1.08% $ 50.9m | |
| Co-Founder & Vice Chairman of the Board | 17.8yrs | US$284.72k | 0.22% $ 10.3m | |
| CFO & Treasurer | less than a year | geen gegevens | 0.092% $ 4.3m | |
| COO & Senior VP of Compliance | less than a year | geen gegevens | 0.055% $ 2.6m | |
| Vice President of Marketing & Corporate Development | no data | geen gegevens | geen gegevens | |
| Executive Director of Sales | less than a year | geen gegevens | geen gegevens | |
| Executive Director of Human Resources | 2.8yrs | geen gegevens | geen gegevens | |
| Senior Director of Business Development & Corporate Strategy | no data | geen gegevens | geen gegevens |
0.8yrs
Gemiddelde duur
49yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ADMA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 17.8yrs | US$6.04m | 1.08% $ 50.9m | |
| Co-Founder & Vice Chairman of the Board | 17.8yrs | US$284.72k | 0.22% $ 10.3m | |
| Independent Director | 12.4yrs | US$280.72k | 0.026% $ 1.2m | |
| Independent Chairman | 17.8yrs | US$290.22k | 0.022% $ 1.1m | |
| Independent Director | 3yrs | US$272.34k | 0.098% $ 4.6m | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 12.3yrs | US$275.09k | 0.061% $ 2.9m | |
| Member of Scientific Advisory Board | 10.3yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 10.3yrs | geen gegevens | geen gegevens | |
| Independent Director | less than a year | US$231.12k | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens |
12.3yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ADMA zijn ervaren en ervaren (gemiddelde ambtstermijn van 12.3 jaar).